trending Market Intelligence /marketintelligence/en/news-insights/trending/XZ9qFw_M54JpFxAtrEo1xg2 content esgSubNav
In This List

Bioblast seeking strategic alternatives to execute business objectives

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Bioblast seeking strategic alternatives to execute business objectives

Bio Blast Pharma Ltd. said it is exploring strategic business alternatives, including possible partnership and merger opportunities.

The clinical stage biotechnology company is considering options such as potential development and commercial partners for its investigational proprietary intravenous form of trehalose. Trehalose has been tested in humans with ocular pharyngeal muscular dystrophy and spinocerebellar ataxia type 3.

Bioblast has hired JSB-Partners to help the company execute its business development objectives.